Cynata Therapeutics Limited (ASX:CYP) Secures $8.1 Million Placement

Funding and Share Placement Details

Cynata Therapeutics Limited (ASX: CYP) has secured commitments for $8.1 million through an institutional placement. This consists of $8 million from the issuance of 44,444,445 new, fully paid ordinary shares at $0.18 per share, and an additional $0.1 million through a conditional placement for Directors, pending shareholder approval.

Clinical Trial Success

The funding announcement follows the successful completion of a Phase 1 clinical trial for CYP-006TK in treating Diabetic Foot Ulcers (DFU). The trial met its primary goal of safety and showed promising efficacy data, demonstrating improved wound healing compared to standard care.

CEO’s Comments on Future Prospects

Dr Kilian Kelly, CEO and Managing Director of Cynata, expressed gratitude for the strong support from both new and existing investors. He stated, “The support received indicates strong confidence in our various clinical programs and their upcoming catalysts.” He also highlighted the company’s optimistic outlook for upcoming trial results in graft-versus-host disease, osteoarthritis, and kidney transplant over the next 18 months.

Strategic Use of Funds

The capital raised will enhance Cynata’s cash position, supporting ongoing clinical development across multiple programs. It will facilitate engagement with regulatory bodies, advance licensing partnerships, and prepare for future clinical trials.

Market Context

The placement was conducted at a discount to recent trading prices, with a 16.3% reduction from the last closing price prior to the announcement. The date for the general meeting to secure Director Placement approval is set for January 2025.

View Original Accouncement

here

Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.